Search
Legend Biotech Corp
LEGNAdd to Watchlist
28.840USD
+0.170+0.59%
Market hours （ET）Quotes delayed by 15 min
5.33BMarket Cap
LossP/E TTM
More Details of Legend Biotech Corp Company
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Legend Biotech Corp Info
Ticker SymbolLEGN
Company nameLegend Biotech Corp
IPO dateJun 04, 2020
CEOHuang (Ying)
Number of employees2600
Security typeDepository Receipt
Fiscal year-endJun 04
Address2101 Cottontail Lane
CitySOMERSET
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08873
Phone17328505598
Websitehttps://investors.legendbiotech.com/
Ticker SymbolLEGN
IPO dateJun 04, 2020
CEOHuang (Ying)
Company Executives of Legend Biotech Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
107.18K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
12.90K
+40.88%
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Independent Director
Independent Director
--
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Mr. Wai Man (Philip) Yau, CPA
Mr. Wai Man (Philip) Yau, CPA
Independent Director
Independent Director
--
--
Dr. Fangliang (Frank) Zhang, Ph.D.
Dr. Fangliang (Frank) Zhang, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
--
-100.00%
Dr. Patrick Casey, Ph.D.
Dr. Patrick Casey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
107.18K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
12.90K
+40.88%
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Independent Director
Independent Director
--
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Mr. Wai Man (Philip) Yau, CPA
Mr. Wai Man (Philip) Yau, CPA
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
803.60M
78.10%
Europe
198.70M
19.31%
China
26.60M
2.59%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, May 4
Updated: Mon, May 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.71%
Suvretta Capital Management, LLC
3.56%
HHLR Advisors, Ltd.
3.29%
Deerfield Management Company, L.P.
3.19%
Westfield Capital Management Company, L.P.
3.10%
Other
75.15%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.71%
Suvretta Capital Management, LLC
3.56%
HHLR Advisors, Ltd.
3.29%
Deerfield Management Company, L.P.
3.19%
Westfield Capital Management Company, L.P.
3.10%
Other
75.15%
Shareholder Types
Shareholders
Proportion
Investment Advisor
21.28%
Investment Advisor/Hedge Fund
13.09%
Hedge Fund
11.91%
Research Firm
2.31%
Corporation
1.22%
Sovereign Wealth Fund
0.68%
Venture Capital
0.45%
Bank and Trust
0.34%
Insurance Company
0.17%
Other
48.54%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
554
93.85M
50.74%
-15.56M
2025Q4
557
89.47M
48.45%
-20.36M
2025Q3
547
88.17M
47.77%
-17.67M
2025Q2
545
89.45M
48.54%
-25.68M
2025Q1
566
91.15M
49.68%
-26.78M
2024Q4
546
104.37M
56.89%
-4.12M
2024Q3
521
96.19M
52.43%
-11.10M
2024Q2
501
96.66M
52.77%
-1.31M
2024Q1
490
91.55M
50.22%
-3.47M
2023Q4
482
91.08M
50.06%
-4.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
21.75M
11.76%
-3.45M
-13.70%
Dec 31, 2025
Suvretta Capital Management, LLC
6.61M
3.57%
+2.79M
+73.09%
Dec 31, 2025
HHLR Advisors, Ltd.
6.11M
3.3%
-192.40K
-3.05%
Dec 31, 2025
Deerfield Management Company, L.P.
5.93M
3.21%
+2.97M
+100.25%
Dec 31, 2025
Westfield Capital Management Company, L.P.
6.16M
3.33%
+70.19K
+1.15%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
3.09M
1.67%
+45.93K
+1.51%
Dec 31, 2025
Point72 Asset Management, L.P.
2.78M
1.51%
+2.78M
--
Dec 31, 2025
Artisan Partners Limited Partnership
2.34M
1.27%
-206.88K
-8.12%
Dec 31, 2025
Genscript Biotech Corp
2.25M
1.22%
--
--
Feb 15, 2026
Goldman Sachs & Company, Inc.
2.16M
1.17%
+1.14M
+110.52%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Harbor Health Care ETF
6.72%
Matthews Emerging Markets Sustainable Future Active ETF
3.84%
Matthews Emerging Markets Discovery Active ETF
3.64%
Global X Genomics & Biotechnology ETF
3.25%
Tema Oncology ETF
2%
Virtus LifeSci Biotech Products ETF
1.37%
KraneShares MSCI All China Health Care Index ETF
1.1%
JPMorgan Healthcare Leaders ETF
0.44%
iShares Biotechnology ETF
0.37%
Main Thematic Innovation ETF
0.36%
View more
Harbor Health Care ETF
Proportion6.72%
Matthews Emerging Markets Sustainable Future Active ETF
Proportion3.84%
Matthews Emerging Markets Discovery Active ETF
Proportion3.64%
Global X Genomics & Biotechnology ETF
Proportion3.25%
Tema Oncology ETF
Proportion2%
Virtus LifeSci Biotech Products ETF
Proportion1.37%
KraneShares MSCI All China Health Care Index ETF
Proportion1.1%
JPMorgan Healthcare Leaders ETF
Proportion0.44%
iShares Biotechnology ETF
Proportion0.37%
Main Thematic Innovation ETF
Proportion0.36%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
